Loading
Latest filing published 29 Dec 2025 for Indaptus Therapeutics, Inc., €91k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Michael James Newman (senior executive) discloses dealings in Indaptus Therapeutics, Inc. to SEC (Form 4). We count 3 filings; the first trade dates from 31 January 2022 and the latest from 22 December 2025.
The open-market record consists of 2 sales worth €89k, with no purchase. Outside the open market, there are 1 share grant.
On 29 December 2025 came the latest disclosure, a share grant for €91k in Indaptus Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations